Abstract
I want to thank the Editor for bringing attention to the effect of a potential shortage of hydroxychloroquine (HCQ) on existing patients with autoimmune diseases during the current COVID-19 crisis [1]. The drug has shown some promising results against SARS-CoV-2, although more testing needs to be done. However, hydroxychloroquine is also an effective medication for patients with autoimmune disorders like systemic lupus erythematosus [2].